Video Experimental Relacionado
Updated: Jul 3, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.6K
Perfilado Inmunitario Multirregional Revela Patrones Pronósticos en el Cáncer de Vejiga
Nadia Jurczok1, Gabriel Dernbach2, Benedikt Ebner3
1Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
European urology oncology
|December 31, 2025
Resumen
Un novedoso panel de proteínas de puntos de control inmunitario (ICP) estratifica eficazmente el riesgo de cáncer de vejiga invasivo muscular (MIBC), superando la estadificación actual. Este enfoque de perfilado inmunitario guía el pronóstico y las decisiones de tratamiento para mejores resultados del paciente.
Área de la Ciencia:
- Oncología; Inmunología; Patología
Sus antecedentes:
- El cáncer de vejiga invasivo muscular (MIBC) es una enfermedad heterogénea con pronóstico variable.
- Los marcadores pronósticos convencionales para MIBC son limitados.
- El microambiente tumoral inmunológico (TIME) es cada vez más reconocido como un factor crucial en la progresión de la enfermedad y los resultados de los pacientes.
Objetivo del estudio:
- Investigar el valor pronóstico de las proteínas de puntos de control inmunitario (ICP) en el TIME de pacientes con MIBC.
- Desarrollar un modelo robusto de estratificación del riesgo para MIBC basado en la expresión de ICP.
- Determinar el número óptimo de biopsias tumorales para un perfilado inmunitario completo.
Principales métodos:
- Análisis de 251 pacientes con MIBC sometidos a cistectomía.
- Cuantificación de seis ICP (IDO, PD-L1, PD-1, LAG-3, TIM-3, VISTA) mediante inmunohistoquímica en núcleos tumorales.
- Agrupación jerárquica de células inmunitarias y tumorales positivas para ICP para definir subtipos de TIME.
- Modelos multivariables de Cox para evaluar la asociación con la supervivencia general (SO) y la supervivencia libre de enfermedad (SLE).
- Remuestreo de bootstrap para estimar el número mínimo de muestras tumorales para la expresión máxima de ICP.
Principales resultados:
- Las células inmunitarias IDO+ y VISTA+ fueron dominantes; las células tumorales PD-L1+ mostraron una expresión dicotómica.
- Tres núcleos espacialmente distintos fueron suficientes para la mayoría de las ICP, mientras que se necesitaron cuatro para otras.
- Se identificaron tres subtipos de TIME (CID1-3), y el CID3 mostró un pronóstico significativamente peor (mediana de SO 18,5 frente a 100,5 meses, p=0,0007).
- La clasificación basada en ICP mejoró la estratificación de pacientes en comparación con la estadificación de la Unión Internacional contra el Cáncer, especialmente en MIBC en etapa tardía.
Conclusiones:
- Un panel de ICP multirregional de seis marcadores proporciona una estratificación del riesgo robusta e independiente de la etapa para MIBC.
- Se recomiendan al menos cuatro biopsias para el perfilado inmunitario de rutina en MIBC.
- Se justifica una validación externa longitudinal adicional de este modelo de estratificación basado en ICP.
Videos de Conceptos Relacionados
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...